UK warns about 'skinny jabs' if trying to get pregnant
skinny jabs
" to fight weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies.
The Medicines and Healthcare products Regulatory Agency (MHRA) said popular jabs like
Ozempic and Wegovy
"must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding".
It urged women to use "effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant".
"Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible... because there is not enough safety data to know whether taking the medicine could cause harm to the baby," it added.
Rebecca Reynolds, a professor of metabolic medicine at the University of Edinburgh, said there was "hardly any available data from human studies" to know if the weight loss drugs were safe in pregnancy.
"The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans," she added.
The MHRA also warned about the impact of another weight-loss and diabetes injection, Mounjaro, on the effectiveness of oral contraception for people who are overweight.
"Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," it said.
Ying Cheong, a consultant in reproductive medicine at the University of Southampton, called the MHRA's advice "both timely and necessary".
"Gastrointestinal side-effects such as vomiting and diarrhoea can impair oral contraceptive absorption, increasing the risk of unintended pregnancy," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
Serena Williams opens up on using weight loss medication: ‘I do everything but shortcuts'
Tennis champion Serena Williams, in a recent interview with NBC's Today, revealed that she is currently taking weight loss medication. She shared that she has been struggling to reach her target weight despite a strict diet and exercise routines. The 42-year-old athlete told the news outlet that her weight loss journey became particularly challenging following the births of her daughters, Olympia in 2017 and Adira in 2023. 'As an athlete and as someone who has done everything, I just couldn't get my weight to where I needed it to be at a healthy place. And believe me, I don't take shortcuts. I do everything but shortcuts,' Williams said. Williams recalled spending hours running and walking after Olympia's birth, even while competing professionally, but said her body would plateau. 'I would always lose a lot of weight, and then I would stay. No matter what I did, I couldn't go lower than that one number,' she explained. The 23-time Grand Slam champion added that her decision was also influenced by health concerns, including a family history of diabetes. African American adults, she noted, face a higher risk of developing the condition. She also wanted to ease the strain on her knees. 'I had a lot of issues with my knees, especially after I had my kid. That, quite frankly, definitely affected maybe some wins that I could have had in my career,' she admitted. On Thursday, Williams also launched a campaign with Ro, a company that prescribes GLP-1 medications through telehealth. The initiative aims to challenge the perception that using weight loss drugs is an 'easy way out.' Her husband, Reddit co-founder Alexis Ohanian, is an investor in Ro and serves on its board. Williams now joins a growing list of public figures who have spoken about turning to weight loss medications. Oprah Winfrey, Whoopi Goldberg, Meghan Trainor, and basketball icon Charles Barkley — a Ro ambassador-- have all shared similar experiences. Comedian Amy Schumer has also said she tried Ozempic but stopped due to side effects. Williams revealed that she began using GLP-1 receptor agonists, a class of drugs that includes Ozempic, Wegovy and Mounjaro, nearly a year ago. These medications work by suppressing appetite and are also used in diabetes treatment. Since starting the regimen in April, the four-time Olympic gold medallist said she has already lost 31 pounds.
NDTV
4 hours ago
- NDTV
Could Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet Obesity
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro have stolen global attention. Now, researchers are turning their focus to dogs, especially breeds like pugs, beagles, and labradors that are often at risk of obesity. The idea is simple but surprising: if GLP-1 drugs work for people, could they help pets too? The Birth Of 'Ozempup' According to a Daily Mail report, biotech firm Vivani Medical has joined hands with Okava to work on a canine-friendly version of these medications. Informally called "Ozempup," the treatment aims to help overweight dogs manage their weight better. How It Works Unlike humans, who usually take weekly injections, dogs would receive the medication through a small implant called OKV-119, reported The Times of India. About the size of a microchip, the implant is placed under the skin and releases a steady dose for up to six months. Early trials in cats suggest the process is safe, and if dog trials go well, the product could be available by 2028. Why Dogs Need Extra Help Scientists say there is a need for such solutions because some dogs are genetically wired to overeat. Professor Alex German from the University of Liverpool explained, "There's a massive genetic component that drives the animal to be hungry all the time. Having an alternative approach, such as drugs, could be useful for clinicians to have another option." For years, vets have relied on diet plans and exercise advice, but these approaches do not always work, especially for dogs with strong genetic tendencies. Owners often find themselves struggling with guilt and frustration when their pets do not lose weight. Concerns And Caution Still, experts urge caution. Dr. Helen Zomer from the University of Florida pointed out that more evidence is needed. "We don't have definitive answers on whether it would be a good solution or the potential consequences," she said. Lessons From The Past The discussion also brings back memories of Pfizer's attempt in 2007, when they introduced Slentrol, a drug meant to control appetite in dogs. It eventually had to be discontinued due to reported side effects like low energy and decreased happiness in pets. What Owners Should Do For Now For now, regular walks, balanced diets, and active play remain the safest ways to keep pets healthy. Whether "Ozempup" becomes a trusted option for vets and owners is something only time will reveal. But if successful, it could mark a big shift in how the pet obesity challenge is handled. At the end of the day, the goal is the same: giving dogs longer, healthier, and happier lives.
Mint
4 hours ago
- Mint
Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts
COPENHAGEN, Aug 21 (Reuters) - As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years. Now sales are slowing and layoffs loom. Annual reports show that Novo's workforce grew from around 43,260 employees in 2019 to 77,350 by the end of last year - an average of 131 new roles filled each week, far faster than rival Eli Lilly, whose headcount rose from 36,000 to 47,000 over the same period. Novo's rapid expansion is now under scrutiny from investors and even management, with the drugmaker facing cost pressure and heightened competition from Lilly's Zepbound and cheaper weight loss copycat compounds in the United States. "I don't want to limit myself in terms of where I look for savings, and salaries are a cost item. I will go through everything," said CEO Maziar Mike Doustdar on August 7, his first day in the job. Two weeks later, on Wednesday, Novo said it had implemented a global hiring freeze for non-critical roles. When asked for details of headcount reduction plans, a company spokesperson referred Reuters to Doustdar's comments. The five-year hiring surge saw employee costs almost double to nearly $9.9 billion by last year, company filings show. While the increased overhead barely registered as sales shot up, Novo's gross margin has been squeezed this year, reaching its lowest level in two and a half years in the second quarter. The stock market has wiped $490 billion off the company's market capitalisation since a peak last year when it was Europe's most valuable firm. It appointed Doustdar to turn things around after twice warning on profit this year and saying sales could dip in the second half of 2025 from a year earlier. "Their earnings had been so strong that you could ignore the cost side," said Lars Hytting, head of trading at Denmark-based investment firm ArthaScope, which holds Novo shares, adding the firm had grown "complacent" and now needed to slim down. 'Novo is now going on Wegovy.' SALES JOBS SEEN AT RISK Some analysts anticipate layoffs in the sales division - a common industry cost-cutting measure. Novo hinted at this during its second-quarter results, saying it would begin deprioritising sales of Rybelsus, its older type 2 diabetes treatment. Sales of the drug have declined, eclipsed by soaring demand for Ozempic, which shares the same active ingredient as Wegovy. "That is probably not a coincidence," said TD Cowen analyst Michael Nedelcovych. "When companies try to cut costs, they probably look first to a sales force for an ailing drug." Novo built a new U.S. sales force to market Wegovy to doctors rather than rely on staff who were already promoting Ozempic, three former employees familiar with the drug's launch told Reuters. That meant more costs, and at times the teams overlapped in outreach to the same healthcare providers, they said. All asked not to be named in order to speak frankly about a former employer. The Novo Nordisk spokesperson declined to comment on the structure of its business. In response to the initial unprecedented demand for Wegovy, Novo also invested billions to expand factories in Denmark and the United States. The company said in early 2024 that around 70% of new hires in the previous two to three years were in the manufacturing division. The spokesperson said that last year, 49% of new hires were related to manufacturing, including around 3,200 employees from Catalent, a contract drugmaker acquired last year by Novo Holdings, Novo Nordisk's controlling shareholder. Novo could also first turn to functions such as communications or administrative roles for cuts, because reductions in sales or manufacturing could hinder its ability to regain market share, said Simon Birkso Larsen, founder and head of Pipeline Clarity, a Copenhagen-based pharmaceutical industry consultancy that does not count Novo as a client. Larsen was a Novo Nordisk employee from 2015 to 2017. "Novo hired so rapidly that it has become difficult to figure out who does what in the are limits to how many people you can integrate and still be effective," he said. ($1 = 6.3995 Danish crowns) (Reporting by Maggie Fick and Jacob Gronholt-Pedersen; Editing by Adam Jourdan, Michele Gershberg and Kirsten Donovan) Disclaimer: This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
